Nuria Codina

Nuria Codina

Auto-generated profile, based on publicly available information

Nuria Codina

Neoleukin Therapeutics Inc., Seattle, WA, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2020 in Science
Verified
Journal Article
Open access
PDF file
TLThomas W. Linsky
Thomas W. Linsky
RVRenan Vergara
Renan Vergara
NCNuria Codina
Nuria Codina
JNJorgen W. Nelson
Jorgen W. Nelson
MWMatthew J. Walker
Matthew J. Walker
DSDaniel-Adriano Silva
Daniel-Adriano Silva
A decoy to neutralize SARS-CoV-2: Many efforts to develop therapies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are focused on the interaction between the spike protein, which decorates the surface of the virus, and its host receptor, human angiotensin-converting enzyme 2 (hACE2). Linsky et al. describe a de novo design strategy that allowed them to engineer decoy proteins that bind to the spike protein by replicating the hACE2 interface. The best decoy, CTC-445, bound with low nanomolar affinity, and selection of viral mutants that decrease binding is unlikely because this would also affect binding to hACE2. A bivalent version of CTC-445 bound even more tightly, neutralized SARS-CoV-2 infection of cells, and protected hamsters from a SARS-CoV-2 challenge. The stable decoy has the potential for respiratory therapeutic delivery. Science , this issue p. 1208

23 May 2012 in Inorganic Chemistry
Verified
Journal Article
Closed access
JJJoaquim Jornet-Somoza
Joaquim Jornet-Somoza
NCNúria Codina-Castillo
Núria Codina-Castillo
MDMercè Deumal
Mercè Deumal
FMFernando Mota
Fernando Mota
JNJuan J. Novoa
Juan J. Novoa
JWJan L. Wikaira
Jan L. Wikaira

1 March 2019 in Journal of Molecular Biology
Verified
Journal Article
Open access
NCNuria Codina
Nuria Codina
DHDavid Hilton
David Hilton
CZCheng Zhang
Cheng Zhang
NCNesrine Chakroun
Nesrine Chakroun
SAShahina S. Ahmad
Shahina S. Ahmad
PDPaul A. Dalby
Paul A. Dalby
Protein aggregation is the underlying cause of many diseases, and also limits the usefulness of many natural and engineered proteins in biotechnology. Better mechanistic understanding and characterization of aggregation-prone states is needed to guide protein engineering, formulation, and drug-targeting strategies that prevent aggregation. While several final aggregated states-notably amyloids-have been characterized structurally, very little is known about the native structural conformers that initiate aggregation. We used a novel combination of small-angle x-ray scattering (SAXS), atomistic molecular dynamic simulations, single-molecule Förster resonance energy transfer, and aggregation-prone region predictions, to characterize structural changes in a native humanized Fab A33 antibody fragment, that correlated with the experimental aggregation kinetics. SAXS revealed increases in the native state radius of gyration, Rg, of 2.2% to 4.1%, at pH 5.5 and below, concomitant with accelerated aggregation. In a cutting-edge approach, we fitted the SAXS data to full MD simulations from the same conditions and located the conformational changes in the native state to the constant domain of the light chain (CL). This CL displacement was independently confirmed using single-molecule Förster resonance energy transfer measurements with two dual-labeled Fabs. These conformational changes were also found to increase the solvent exposure of a predicted APR, suggesting a likely mechanism through which they promote aggregation. Our findings provide a means by which aggregation-prone conformational states can be readily determined experimentally, and thus potentially used to guide protein engineering, or ligand binding strategies, with the aim of stabilizing the protein against aggregation.

20 May 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
NCNuria Codina
Nuria Codina
CZCheng Zhang
Cheng Zhang
NCNesrine Chakroun
Nesrine Chakroun
PDPaul A. Dalby
Paul A. Dalby
Successful development of protein therapeutics depends critically on achieving stability under a range of conditions, while retaining their specific mode of action. Gaining a deeper understanding of the drivers of instability across different stress conditions, will potentially enable the engineering of protein scaffolds that are inherently manufacturable and stable. Here, we compared the structural robustness of a humanized antibody fragment (Fab) A33 using atomistic molecular dynamics simulations under two different stresses of low pH and high temperature. RMSD calculations, structural alignments and contact analysis revealed that low pH unfolding was initiated through loss of contacts at the constant domain interface (C L -C H 1), prior to C L domain unfolding. By contrast, thermal unfolding began with loss of contacts in both the C L -C H 1 and variable domain interface (V L -V H ), followed by domain unfolding of C L and also of V H , thus revealing divergent unfolding pathways. FoldX and Rosetta both agreed that mutations at the C L -C H 1 interface have the greatest potential for increasing the stability of Fab A33. Additionally, packing density calculations found these residues to be under-packed relative to other inter-domain residues. Two salt bridges were identified that possibly drive the conformational change at low pH, while at high temperature, salt bridges were lost and reformed quickly, and not always with the same partner, thus contributing to an overall destabilization. Sequence entropy analysis of existing Fab sequences revealed considerable scope for further engineering, where certain natural mutations agreed with FoldX and Rosetta predictions. Lastly, the unfolding events at the two stress conditions exposed different predicted aggregation-prone regions (APR), which would potentially lead to different aggregation mechanisms. Overall, our results identified the early stages of unfolding and stability-limiting regions of Fab A33, which provide interesting targets for future protein engineering work aimed at stabilizing to both thermal and pH-stresses simultaneously. Author Summary: Currently, antibody-based products are the most rapidly growing class of pharmaceuticals due to their high specificity towards their targets, such as biomarkers on the surface of cancer cells. However, they tend to aggregate at all stages of product development, which leads to decreased efficiency and could elicit an immunological response. Improvements in the stability of therapeutic antibodies are generally made during the development phase, by trial and error of the composition of the formulated product, which is both costly and time consuming. There is great demand and potential for identifying the drivers of instability across different stress conditions, early in the discovery phase, which will enable the rational engineering of protein scaffolds. This work elucidated the stability-limiting regions of the antibody fragment Fab A33 using several computational tools: atomistic molecular dynamics simulations, in-silico mutational analysis by FoldX and Rosetta, packing density calculators, analysis of existing Fab sequences and predictors of aggregation-prone regions. Results identified particular regions in which mutagenesis has the potential to stabilize Fab against both thermal and pH-stresses simultaneously. Overall, the methodology used here could improve the developability screening of candidate antibody products for many diseases, such as cancer, chronic inflammatory diseases and infectious diseases.